Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ventricular assist with heparin surface coated devices.

L K von Segesser1, B M Weiss, B Bisang

  • 1Clinic for Cardiovascular Surgery, University Hospital, Zürich, Switzerland.

ASAIO Transactions
|July 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

How to prevent venous cannula orifice obstruction during extracorporeal circulation.

Perfusion·2014
Same author

Classifying ultra-high risk smoldering myeloma.

Leukemia·2014
Same author

Association between mobilization regimen and PFS after auto-SCT for multiple myeloma.

Bone marrow transplantation·2014
Same author

Bone marrow angiogenesis in myeloma and its precursor disease: a prospective clinical trial.

Leukemia·2013

Heparin-coated ventricular assist devices (VADs) enable effective ventricular assist without systemic anticoagulation, reducing risks associated with heparin use.

Area of Science:

  • Biomedical Engineering
  • Cardiovascular Science
  • Medical Device Technology

Background:

  • Systemic heparinization is standard for ventricular assist devices (VADs).
  • Heparin poses bleeding risks and complications.
  • Alternative anticoagulation strategies for VADs are needed.

Purpose of the Study:

  • To evaluate the efficacy and safety of heparin-surface-coated VADs.
  • To compare coated VADs used without systemic heparinization against uncoated VADs with systemic heparinization.
  • To determine if VAD function can be maintained without systemic anticoagulation.

Main Methods:

  • Bovine experiments (n=8) were conducted using heparin-coated and uncoated VADs.
  • Systemic heparinization was administered to the control group (300 IU/kg).

Related Experiment Videos

  • Key parameters including activated clotting time (ACT), platelet count, plasma hemoglobin, LDH, and VAD clot scores were monitored.

    • Main Results:

    • Coated VADs maintained stable ACT without systemic heparinization.
    • Uncoated VADs showed significantly higher ACT values when systemically heparinized.
    • No significant differences were observed in platelet depletion, plasma hemoglobin, LDH, or VAD clot scores between groups.
    • No VAD occlusions occurred in either group.

    Conclusions:

    • Heparin-surface-coated VADs can achieve effective ventricular assist without systemic heparinization.
    • This approach may reduce the risks associated with systemic anticoagulation.
    • Further improvements in VAD technology could facilitate routine use without systemic heparinization.